Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals, Cellumen to Develop and Sell Cytotoxicity Panel and Services

NEW YORK, Feb. 7 (GenomeWeb News) - Serologicals has signed an agreement with Cellumen to commercialize a cytotoxicity profiling panel and services, Serologicals said today.


The system will be designed with cellular assay reagents from Serologicals' Chemicon and Upstate units and with Cellumen's system cell biology approach, the company said in a statement.


Chemicon will focus on the development and production of assays and panels, while Cellumen will focus on their use on profiling services.


The companies will market the products jointly.


No additional details were provided.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.